

CAGRILINTIDE ACETATE 10 MG INJECTION
Drug Class: Amylin Analog
Composition:
- Active Substance: Cagrilintide Acetate
- Concentration: 10 mg/vial
Presentation: 2 mL Vial
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report
Ca
grilintide Acetate 10 mg by Dragon Pharma is a synthetic amylin analog developed to enhance satiety, suppress appetite, and support weight loss. It mimics the effects of the naturally occurring hormone amylin, which works in tandem with insulin to help regulate gastric emptying and food intake.
Cagrilintide is a long-acting amylin receptor agonist designed for subcutaneous use. It helps reduce caloric intake by delaying gastric emptying and promoting a sense of fullness. According to published clinical trials, Cagrilintide has shown synergistic effects when combined with GLP-1 analogs, making it a promising agent in obesity management.
This research-grade version of Cagrilintide by Dragon Pharma is formulated at 10 mg per 2 mL vial, offering consistent dosing and purity. Produced in Europe under GMP conditions and lab tested for authenticity, it is trusted by medical researchers and advanced users pursuing cutting-edge metabolic support.
Cagrilintide is administered via subcutaneous injection. Research protocols typically involve once-weekly dosing, often starting between 0.3–0.6 mg and titrating up to 2.4 mg or more depending on study goals. The 10 mg vial allows multiple titrated doses. Note: For research purposes only. Not approved for medical or dietary use.
Ideal for advanced users or researchers exploring novel weight loss strategies, especially when stacked with GLP-1 therapies. It's gaining popularity in cutting-edge metabolic research, particularly for those with obesity, insulin resistance, or appetite dysregulation.
Cagrilintide is a synthetic amylin analog used in research for appetite suppression, delayed gastric emptying, and weight loss. It mimics the natural hormone amylin, which works with insulin to regulate food intake.
Cagrilintide is administered via subcutaneous injection. In research, it is commonly dosed once weekly. Dosage depends on study goals, often starting low and titrating upward.
Yes. Cagrilintide is often studied in combination with GLP-1 receptor agonists like Semaglutide, showing synergistic effects on weight loss and appetite control.
Reported benefits include reduced appetite, prolonged satiety, lower caloric intake, and steady fat loss. It is non-stimulant and typically well-tolerated in research settings.
Yes. Dragon Pharma Cagrilintide 10 mg is lab-tested for purity and concentration. It is manufactured under strict GMP standards and includes a lab report for transparency.
Please log in to write Cagrilintide 10 mg review.
PENTADECAPEPTIDE 2 MG INJECTION
Drug Class: Healing/Repair Peptide
Composition:
- Active Substance: Pentadecapeptide
- Concentration: 5 mg/vial
Presentation: 5 mL Vial
Form: Powder
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report
TIRZE-PEP 5 MG INJECTION
Drug Class: Dual GLP-1/GIP Peptide
Composition:
- Active Substance: Tirzepatide
- Concentration: 5 mg/vial
Presentation: 2 mL Vial
Form: Powder
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report